Ryoncil is an allogeneic mesenchymal stromal cell (MSC) therapy indicated for the treatment of acute graft-versus-host ...

Mesoblast Limited ( ($AU:MSB) ) has provided an announcement. Mesoblast Limited announced that its CEO, Silviu Itescu, will ...

Manufacturing: As a result of FDA approval of RYONCIL in December 2024, the US$23.0 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now ...

Mesoblast stock surged after FDA approval of Ryoncil for SR-aGVHD, but market size is limited with NPV of ~$1B vs $2.33B market cap. Ryoncil faces commercialization challenges: second-line therapy ...

Ryoncil® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months and ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

At its third attempt, Mesoblast has secured FDA approval for Ryoncil as a treatment for children with graft-versus-host disease, the first-ever approval for a mesenchymal stromal cell (MSC ...

Ryoncil is an allogeneic mesenchymal stromal cell (MSC) therapy indicated for the treatment of acute graft-versus-host disease (aGvHD) for children older than two months, including adolescents and ...

FDA approved Ryoncil® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR ...